Navigation Links
Yongye Biotechnology Announces Record Third Quarter Results
Date:11/13/2008

p>

EQUIVALENTS 6,839,421 1,443,690

CASH AND CASH EQUIVALENTS -

BEGINNING 8,137 89,023

CASH AND CASH EQUIVALENTS -

ENDING $6,847,558 $1,532,713

Supplemental cash flow information:

Cash paid for income taxes 424,725 --

Cash paid for interest expense

payment -- 138,955

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Phone: +1-818-390-1272

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
2. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
3. Yongye Biotechnology International Raises $9.4 Million in Private Placement
4. Yongye Biotechnology International Announces Second Quarter Results
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Retains CCG Investor Relations
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
9. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
10. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... ROCKLAND, Mass. , April 16, 2015 /PRNewswire/ ... of Merck KGaA, Darmstadt, Germany ... Senior Vice President, Head of Global Clinical Development. ... development expertise, including experience in Oncology and Immunology. ... leadership ability, having served as a Vice President ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... personalized immune therapies for cancer, announced today that ... Immunotherapy Index (LCINDX), a professional index recently established ... within the biotechnology space.  The ... in the immunotherapy space, including 6 big pharma ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... Biopharmaceuticals (Nasdaq: KERX ) today announced completion ... its Phase 3 registration program of Zerenex™, the Company,s ... serum phosphorus levels, or hyperphosphatemia, in patients with end-stage ... registration program, which is being conducted pursuant to a ...
... NEW HAVEN, Conn., Sept. 19, 2011 The U.S. ... of allowance related to Cenestra Health,s high-purity omega-3 fatty ... claims cover a range of high-purity omega-3 formulations including ... Cenestra Health was issued U.S. Patent No. ...
... 16, 2011 Generex Biotechnology Corporation ( www.generex.com ... Napolii, from University Campus Bio-Medico in Rome, Italy, ... on Generex Oral-lyn™ buccal insulin spray on September ... Study of Diabetes (EASD) annual meeting in Lisbon, ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 2Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 4
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... by eating the leaves of an invasive tree that soaks ... down water loss in the Southwestern United States. Two ... U.S. Geological Survey and the U.S. Department of Agriculture, have ... result from using Asian beetles for the biological control of ...
... WEST LAFAYETTE, Ind. - A Purdue University scientist and ... improved plant growth regulators that are expected to be ... of horticulture, said the growth inhibitors block the transport ... the plant, controls growth processes. Current growth regulators that ...
... whose work has overtones of Indiana Jones as they ... that could become the source of life-saving new medicines, ... international agreement on biodiversity will affect their work. That,s ... News (C&EN), ACS,s weekly newsmagazine. C&EN Associate ...
Cached Biology News:Scientists study control of invasive tree in western US 2Scientists study control of invasive tree in western US 3New growth inhibitors more effective in plants, less toxic to people 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors have ... inhibition of eukaryotic RNases of the neutral ... inhibitory effect by noncovalently binding to RNases ... for the binding of RNasin Ribonuclease Inhibitor ...
Biology Products: